ResMed (RMD) just posted quarterly results that topped analyst expectations on both earnings and revenue, while reaffirming its full year outlook and highlighting firm demand for sleep devices, masks, and digital health tools.
ResMed's share price has climbed 13.5% over the past month and 19.8% across the last 90 days, while a 73.5% three year total shareholder return indicates that the recent earnings beat and ongoing dividend payments are reinforcing longer term momentum.
Scan how ResMed's latest beat and dividend affirmation compare with other potential opportunities by reviewing a curated list of 36 healthcare AI stocks in the same broad theme.
After a 13.5% jump in a month and a 19.8% run over 90 days, ResMed now asks a simple question of you: Does the current valuation already reflect this run, or is patience still the better entry strategy?
Most Popular Narrative: 0% Overvalued
On the most followed narrative, ResMed's fair value of $252.69 sits almost exactly on the last close at $252.83. As a result, the story hinges less on a large valuation gap and more on how the business compounds from here.
Supply chain productivity initiatives that have already widened gross margin by roughly 500 to 600 basis points in three years, combined with modest price increases and guidance for low double digit basis point margin improvement each year through 2030, point to an ongoing structural lift to gross margin and free cash flow.
See why 78 investors see ResMed as 0% overvalued .
Result: Fair Value of $252.69 (ABOUT RIGHT)
Still, there are pressure points that could upset this ResMed narrative, including the Astral ventilator corrective action and higher component and freight costs squeezing gross margin.
Find out about the key risks to this ResMed narrative .
Another View: What ResMed's P/E Is Telling You
Analyst fair value pins ResMed almost exactly at the current price, yet the market is pricing the stock at a P/E of 23.3x. That is below peers at 35.4x and under the 26.4x fair ratio. The gap hints at either a cushion or a signal that expectations stay contained. Which do you think it is?
To see how that earnings multiple stacks up in more detail, including peers and the fair ratio the market could move toward, See what the numbers say about this price — find out in our valuation breakdown. .
Next Steps
If the tone of this ResMed discussion feels optimistic, treat it as a starting point rather than a conclusion and quickly pressure test the numbers yourself. Then weigh those positive signals against the full breakdown of 4 key rewards
Looking for more ResMed investment ideas?
ResMed might already be on your radar, but the market is full of other setups that could fit your goals just as well or even better. Use the Simply Wall Street Screener to quickly surface focused shortlists instead of trawling through tickers blindly.
-
Target resilient income potential by scanning a hand picked group of 7 dividend fortresses that put cash returns to shareholders at the center of their story.
-
Hunt for quality at a sensible price by zeroing in on 30 high quality undervalued stocks that pair fundamentals with valuations the market may be overlooking.
-
Protect the downside first by focusing on a 30 resilient stocks with low risk scores that tilts toward sturdier balance sheets and steadier risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include RMD .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
